Current Report Filing (8-k)
November 30 2020 - 05:22PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 30, 2020
Milestone Scientific Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
(State or other jurisdiction
of incorporation)
|
|
001-14053
(Commission
File Number)
|
|
13-3545623
(IRS Employer
Identification No.)
|
|
|
|
425 Eagle Rock Avenue
Suite 403
Roseland, New Jersey
(Address of principal executive offices)
|
|
07068
(Zip Code)
|
Registrant’s telephone number, including area code (973)
535-2717
(Former name or former address, if changed since last report.)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name on exchange on which registered
|
Common Stock
|
MLSS
|
NYSE American
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instructions
A.2. below):
☐ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act
☐
Item 1.01 Entry into a Material Definitive
Agreement.
On November 30, 2020, Milestone Scientific Inc. (the “Company”) and
Wand Dental, Inc., a wholly-owned subsidiary of the Company (“Wand
Dental”) terminated the exclusive rights granted to Henry Schein
Inc. (“Henry Schein”) for distribution of The
Wand®
STA®
Computer Assisted Anesthesia System, including its
disposable, single-use handpiece, and certain related products (the
“Wand STA System”), in the United States and Canada, in
accordance with the Exclusive Distribution and Supply Agreement
dated as of June 20, 2016 (the “Agreement”) between the Company and
Henry Schein. As per the Agreement, Henry Schein will remain a
distributor of the Company for the Wand STA System, albeit
on a non-exclusive basis, for a period of one year from such
termination date. As a result, the Company now looks forward to
implementing a strategy where it will have multiple distributors
throughout the United States and Canada, to broaden its
distribution coverage and marketing coverage. The Company believes
this will allow it to increase its market penetration, with a more
significant return on its marketing dollars.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
Milestone Scientific Inc.
|
|
Dated: November 30, 2020
|
By:
|
/s/ Joseph D’Agostino
|
|
|
|
Joseph D’Agostino
|
|
|
|
Chief Financial Officer
|
|